Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes.

Trial Profile

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 03 Aug 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2008-004412-12).
    • 04 May 2012 Actual patient number 338 added as reported by ClinicalTrials.gov.
    • 04 May 2012 Actual end date Oct 2010 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top